These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3387746)

  • 1. [Adenocarcinoma of the kidney].
    Sonntag RW
    Schweiz Rundsch Med Prax; 1988 May; 77(20):565-6. PubMed ID: 3387746
    [No Abstract]   [Full Text] [Related]  

  • 2. [A clinical study of renal cell carcinoma].
    Morozumi M; Ogawa Y; Tanaka T; Yamaguchi K; Sakamoto Y; Kitagawa R
    Nihon Jinzo Gakkai Shi; 1986 Oct; 28(10):1417-22. PubMed ID: 3820818
    [No Abstract]   [Full Text] [Related]  

  • 3. [Problems in the therapy of kidney neoplasms].
    Masuda F
    Nihon Hinyokika Gakkai Zasshi; 1985 Nov; 76(11):1612-8. PubMed ID: 3835352
    [No Abstract]   [Full Text] [Related]  

  • 4. Renal cell cancer--a multimodal approach to preserving renal function and improving survival.
    Hohenfellner M; Pahernik S; Jaeger D; Zeier M
    Nephrol Dial Transplant; 2011 Oct; 26(10):3086-8. PubMed ID: 21622992
    [No Abstract]   [Full Text] [Related]  

  • 5. Case for nephron-sparing surgery in managing renal cell carcinoma.
    Taylor RJ
    Semin Urol; 1993 May; 11(2):104-11. PubMed ID: 8362119
    [No Abstract]   [Full Text] [Related]  

  • 6. [Outcome of patients in metastatic renal cell carcinoma with or without embolization].
    Masuda F; Nakada J; Takasaka S; Hishinuma H
    Hinyokika Kiyo; 1987 Sep; 33(9):1354-6. PubMed ID: 3434491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine.
    Kotake T; Kinouchi T
    Prog Clin Biol Res; 1989; 303():661-9. PubMed ID: 2780667
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of ex vivo-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study.
    Graham S; Babayan RK; Lamm DL; Sawczuk I; Ross SD; Lavin PT; Osband ME; Krane RJ
    Semin Urol; 1993 Feb; 11(1):27-34. PubMed ID: 8465126
    [No Abstract]   [Full Text] [Related]  

  • 9. [A clinical study of renal cell carcinoma].
    Uchida T; Izumi H; Kobayashi K; Arakawa T; Honda N; Omata T; Odajima K; Mashimo S; Endo T; Ishibashi A
    Hinyokika Kiyo; 1985 Nov; 31(11):1919-25. PubMed ID: 4091134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and molecular markers for renal cell carcinoma.
    Bui MH; Zisman A; Pantuck AJ; Han KR; Wieder J; Belldegrun AS
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):565-75. PubMed ID: 12113089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic factors in kidney cancer].
    Patard JJ
    Prog Urol; 2007 Feb; 17(1 Suppl 1):139-43. PubMed ID: 17571637
    [No Abstract]   [Full Text] [Related]  

  • 12. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autolymphocyte therapy in the treatment of metastatic renal cell carcinoma.
    Sawczuk IS
    Urol Clin North Am; 1993 May; 20(2):297-301. PubMed ID: 8493751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
    Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
    J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal cell carcinoma: urologists in a new era.
    Uzzo RG
    J Urol; 2005 Nov; 174(5):1723-4. PubMed ID: 16217270
    [No Abstract]   [Full Text] [Related]  

  • 16. [Results of combined surgical and radiologic treatment of hypernephroid carcinoma].
    Alheit HD; Pilz U; Schorcht J; Kelly LU
    Radiobiol Radiother (Berl); 1987; 28(4):437-44. PubMed ID: 3685287
    [No Abstract]   [Full Text] [Related]  

  • 17. [Prognostic factors for predicting the success of immunotherapy in metastatic renal cell carcinoma].
    Schmitz-Dräger BJ; Jankevicius F; Otto T
    Urologe A; 1995 May; 34(3):195-9. PubMed ID: 7610511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interferon-alpha therapy in hypernephroma].
    Sagaster KP
    Wien Med Wochenschr; 1993; 143(16-17):443-7. PubMed ID: 8273370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The results of the treatment in renal cell carcinoma].
    Aso Y; Masuda H; Hirose J; Mugiya S; Maruyama M; Mitsuhashi T; Yamaguchi Y; Nakano M; Tsukada T; Suzuki A
    Nihon Hinyokika Gakkai Zasshi; 1988 Jun; 79(6):1096-102. PubMed ID: 3184584
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.